AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2023
Jan 6, 2023
33483_dirs_2023-01-06_9c326e47-976a-4723-a9e4-013d7723349c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2023-01-04
Reporting Person: Kishimoto Takashi Kei (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-04 | Common Stock | S | 6381 | $1.1337 | Disposed | 367719 | Direct |
| 2023-01-04 | Common Stock | S | 11 | $1.145 | Disposed | 367708 | Direct |
| 2023-01-05 | Common Stock | S | 3372 | $1.1293 | Disposed | 364336 | Direct |
| 2023-01-05 | Common Stock | S | 20 | $1.1114 | Disposed | 364316 | Direct |
Footnotes
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
More from Cartesian Therapeutics, Inc.
Regulatory Filings
2026
May 26
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Regulatory Filings
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Regulatory Filings
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8